Barclays PLC Moon Lake Immunotherapeutics Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Barclays PLC holds 5,641 shares of MLTX stock, worth $307,039. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,641
Previous 5,641
-0.0%
Holding current value
$307,039
Previous $283,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.18 Billion34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$462 Million30.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$162 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$151 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$126 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.01B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...